Targeted Oncology· @TargetedOnc · X·· 1 day agoScore70
Body · original
Strong VOLGA Phase III results at #ESMO26!
Perioperative EV + durvalumab in cisplatin-ineligible MIBC:
2-year EFS: 64% vs 45% (HR 0.51)
2-year OS: 78% vs 69% (HR 0.58)
pCR: 45% vs 10%
An important survival advance. Could this redefine care?
76 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com